An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

NCT02531516 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

1503

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostatic Neoplasms

Interventions

DRUG: Apalutamide
DRUG: Bicalutamide
DRUG: Bicalutamide Placebo
DRUG: Apalutamide Placebo
DRUG: GnRH (agonist)
RADIATION: 74-80 Grays (units of radiation)

Sponsor

Aragon Pharmaceuticals, Inc.